Top 5 Stock Picks of James Morrow’s Callodine Capital Management

1. Bristol-Myers Squibb Company (NYSE:BMY)

Callodine Capital Management’s Stake Value: $18,623,000
Percentage of Callodine Capital Management’s Portfolio: 5.97%
Number of Hedge Fund Holders: 70

Bristol-Myers Squibb Company (NYSE:BMY) is an American multinational pharmaceutical company with its headquarters in New York City. On June 5, BofA analyst Geoff Meacham raised his price objective on Bristol-Myers Squibb Company (NYSE:BMY) to $80 from $78 while maintaining a Buy rating on the stock.

According to a statement from Bristol-Myers Squibb Company (NYSE:BMY) Canada, Opdivo was authorized by Health Canada on June 28 as a mono-therapy for the supplementary treatment of adult urothelial carcinoma patients who are at higher risk of recurrence following UC radical resection.

By the end of the first quarter, 70 hedge funds monitored by Insider Monkey were bullish on Bristol-Myers Squibb Company (NYSE:BMY), valued at $2.43 billion. Of the 70 hedge funds, John Overdeck and David Siegel’s Two Sigma Advisors had the most significant stake in Bristol-Myers Squibb Company (NYSE:BMY). As of March 31, the fund’s stake in the company was $18.62 million, covering 5.97% of Callodine Capital Management’s 13F portfolio.

You can also take a peek at Top 10 Stock Picks of Roberto Mignone’s Bridger Management and Top 10 Stock Picks of Alec Litowitz and Ross Laser’s Magnetar Capital.

Follow Insider Monkey on Twitter